Articles tagged with Drug Design
Insilico Medicine CEO Alex Zhavoronkov to discuss AI business potential and economic growth at Fortune Global Forum 2024. The company has developed a generative AI-powered platform that utilizes deep learning techniques for novel target discovery and molecular structure generation.
Adipo Therapeutics' lead product ADPO-002NP shows promising results in increasing energy expenditure and improving insulin resistance by browning white adipose tissue. The company is now raising $8 million to move the treatment to first-in-human Phase I clinical trials.
Rice bioengineers create a mathematical model that challenges long-held assumptions about IL-12's behavior in the body, suggesting repeated doses cause immune cells to hoard IL-12 before it reaches the bloodstream. The findings have significant implications for IL-12 therapy design and may lead to more effective dosing regimens.
Researchers at Linköping University have developed a new version of AlphaFold that can predict the shape of very large and complex protein structures, integrating experimental data. This breakthrough aims to improve the development of new proteins for medical drugs.
A team of MIT engineers developed an algorithm to identify causal links in complex systems, taking data from various sources and analyzing interactions between variables. The method generates a causality map linking variables with likely cause-and-effect relationships, including synergistic and redundant links.
Researchers at MIT have designed tiny particles that can be implanted at a tumor site, delivering heat and chemotherapy to treat cancer. The treatment approach has been shown to completely eliminate tumors in most mice and prolong their survival.
Researchers at Wayne State University are developing new AI-powered methods to design and develop new drugs, including carbohydrate-based treatments for cancer. The study aims to improve the accuracy of simulations and machine learning models to predict the behavior of complex biological molecules.
Researchers have identified a unique multidomain enzyme capable of catalysing two separate reactions, cyclization and hydroxylation, on a single peptide substrate. This breakthrough discovery opens the possibility of developing innovative drug molecules with potential therapeutic applications for life-threatening infections and cancer.
A new study found that initial prescriptions of benzodiazepines for older stroke survivors often include excessive doses, posing a risk of dependence, falls, and other harmful effects. Guidelines recommend avoiding benzodiazepine prescriptions if possible, but some cases may require limited use under close monitoring.
Researchers at University of Dundee have designed a new variant of CRBN protein using innovative molecular
Researchers at EMBL Hamburg and CSSB have uncovered the molecular details of vitamin B1 absorption, revealing critical transporters and barriers that hinder its progress. The study sheds light on rare diseases caused by SLC19A3 mutations and potentially life-threatening hidden deficiencies triggered by certain medications.
A new study reveals that etizolam and gabapentinoids contribute to a rising culture of polydrug use and increased drug-related deaths in Scotland. The analysis of 18 studies found a significant increase in gabapentinoid-related deaths, primarily due to concurrent opioid use.
Concordia researchers develop a novel method of 3D printing using acoustic holograms, capable of creating complex objects quickly and at once. This technique, called holographic direct sound printing (HDSP), stores information of multiple images in a single hologram, allowing for the creation of multiple objects simultaneously.
Rice researchers use a rapidly alternating magnetic field to create direction-dependent structures from superparamagnetic beads, offering precise control over material properties. The study reveals the importance of magnetic relaxation time in controlling particle interactions.
A research team developed an RNA-based sensor platform that can regulate gene expression in bacteria, mimicking natural biological interactions. The START platform enables tunable control over sensor response and detection of various molecules, including drugs and proteins.
A team of researchers has designed a new antimalarial drug called MED6-189, which is effective against both drug-sensitive and drug-resistant strains of human malaria parasites. The compound works by targeting the apicoplast organelle and vesicular trafficking pathways, making it a promising lead in the fight against malaria.
Researchers at UT Austin developed AI model EvoRank to design protein-based therapies and vaccines by leveraging nature's evolutionary processes. The model identifies useful mutations in proteins, offering a new approach to biomedical research and biotechnology.
A study published in Neuron found that psychedelics, such as DOI, activate fast-spiking interneurons in the ventral hippocampus, which helps to silence other neighboring neurons and reduce anxiety in mice and rats. This understanding of brain chemistry could lead to the development of new drugs targeting anxiety.
Scientists used neutrons to identify exact atomic-scale chemistry in serine hydroxy methyltransferase, a metabolic enzyme necessary for cell division. The researchers discovered that a glutamate residue regulates chemical reactions for this enzyme, and designing an inhibitor could block the enzyme's function.
The European capacity for antibiotic research and development requires sustained investment to combat growing resistance. Collaboration and risk-sharing can help keep companies in anti-infective drug development, as a temporary funding strategy may lead to lost efforts.
The LYFE-III study will digitize the intervention and make it freely available, assessing its effectiveness. The current research builds on previous studies that focused on parenting skills enhancement and substance abuse prevention among Latino youth.
The development of vaccine adjuvants has evolved significantly, shifting from empirical methods to a more structured approach grounded in rational drug design. This new era emphasizes the importance of understanding structural and functional traits of adjuvants.
Proteolysis targeting chimeras targeting peroxisome proliferator-activated receptors (PPARs) show promise in overcoming challenges of PPAR-targeted therapies. They offer enhanced tumor specificity due to differential E3 ligase expression, reducing off-target effects and improving therapeutic outcomes.
A UCL-led research team has crystallized the first alternative DNA structure from the insulin gene, revealing its shape and structure. The discovery suggests that different variants in the insulin gene can form different DNA structures, which could affect insulin function and potentially play a role in diabetes development.
A clinical trial led by UC San Francisco aims to develop new therapies for progressive supranuclear palsy, with a focus on reducing time to find effective treatments and increasing diverse participant enrollment. The five-year grant could lead to the first effective drugs for this incurable neurodegenerative disorder.
Researchers investigated peptide clumping behavior using molecular dynamics simulations and AI techniques. They discovered that aromatic amino acids enhance aggregation, while hydrophilic ones inhibit it, offering insights into peptide structure and function.
A study emulated a clinical trial using real-world UK healthcare data to explore treatment effects in patients with atrial fibrillation. The method found similar outcomes between apixaban and warfarin, but with differences linked to ethnicity and medication use.
Researchers characterized bemnifosbuvir's activation cascade at atomic resolution, paving the way for the design of new broad-spectrum antiviral drugs. The study provides insights into the mechanism of action of this antiviral compound, which could lead to more effective treatments against various viral infections.
A new study published in the Stroke journal found that people with brain aneurysms are at higher risk of developing mental health conditions, including anxiety. The study, which analyzed data from over 85,000 people, found that younger adults were particularly vulnerable to this increased risk.
Researchers at Uppsala University used AI to predict the three-dimensional structure of a receptor, identifying molecules that bind to it with higher accuracy than traditional methods. This breakthrough accelerates the development of new drugs for mental health disorders such as schizophrenia and depression.
A deadly marine cone snail's venom contains a toxin that interacts with human cells in a specific manner, regulating blood sugar levels and hormone balance. This discovery may lead to the design of more effective drugs for treating diabetes and endocrine disorders.
The new battery can capture oxygen from air and use it to oxidize zinc, creating a current of up to 1 volt. It powers an actuator, memristor, clock circuit, and sensors, making it ideal for robotics and medical applications.
A new study found that job strain and effort-reward imbalance at work increase the risk of developing atrial fibrillation, an abnormal heart rhythm. The research suggests that recognizing and addressing psychosocial stressors at work can foster healthy environments.
Researchers developed a novel EIT-EVA PCB sensor for non-invasive assessment of drug inhibition on ion channels. The system enables real-time monitoring of ion flow changes in response to drug exposure, offering a faster and more efficient alternative to traditional methods.
Researchers designed a molecule, MTX-531, that impairs signaling drivers of cancer therapy resistance. In mouse models, MTX-531 led to tumor regressions in multiple head and neck cancers, showing a favorable toxicity profile.
Scientists improve stability and bioavailability of mRNA nanocarriers using triphenylphosphonium, leading to increased protein production in tumor tissues. The TPP-based system also shows higher mRNA levels in blood after 30 minutes compared to amine-based micelles.
Studies published in Crystal Growth & Design highlight the suite's ability to visualize and quantify chemical and topological information from crystallographic data. This approach can reduce trial-and-error methods, providing data-driven guidance for formulators and particle engineers.
Researchers at the University of Cambridge have developed an atlas of proteins that reveals how they behave inside human cells. The tool allows for the identification of new proteins involved in important bodily functions, including fat distribution and protein creation.
Researchers describe a new concept for an immune response against cancer and aging using senescent cell-derived vaccines. The vaccines aim to stimulate the immune system against cancer cells and slow down or reverse aging-related diseases.
Researchers develop a method that fuses AlphaFold's strengths with computer simulations based on physics laws to predict protein structures, enabling faster drug development. The approach filters down initial hypotheses to a more manageable set of structures, increasing the effectiveness of pharmaceuticals.
Scientists have identified a mechanism that enables enzymes to communicate and produce organic molecules with disease-fighting properties. This breakthrough could aid in the discovery of new drugs by allowing researchers to design or modify enzymes to create novel natural products.
Researchers have made a breakthrough in understanding the GIP hormone's role in regulating insulin levels and weight loss. The study, involving over 500,000 individuals, found that inhibiting the GIP receptor may result in weight loss, while activating it without arresting its signal is crucial.
Dr. Alice Walker will investigate the design of fluorescent protein sensors using computer simulations, which may aid in tracking diseases and monitoring treatment effectiveness in living cells and organisms. The five-year $690,816 grant also supports undergraduate research opportunities for WSU students.
The researchers created soft robots equipped with electronic skins and artificial muscles to sense their surroundings and adapt in real-time. These robots can perform various tasks, such as monitoring internal conditions, providing treatments, and delivering drugs over an extended period.
Researchers highlight strategies for improving agriculture with nanotechnology, including targeted delivery of pesticides and herbicides, and digital twin simulations. These approaches aim to reduce environmental pollution and increase crop resilience.
Researchers at The Wistar Institute have developed a new, long-lasting antibody treatment called Persistent Multivalent T Cell Engager (CA9-PMTE) that targets clear cell renal cell carcinoma. This innovative therapy has shown promise in pre-clinical models and could potentially be used to treat other difficult-to-treat cancers.
Cleveland Clinic and IBM researchers develop a hybrid framework combining quantum and classical computing methods for protein structure prediction. This approach overcomes limitations of current classical methods and demonstrates improved accuracy in predicting protein structures.
Researchers have designed a method to 'cloak' proteins for targeted delivery into cells, utilizing lipid nanoparticles. The cloaked proteins can be captured by the nanoparticles and exert their therapeutic effect once inside the cell. This approach shows promise for repurposing antibodies and other proteins for cancer treatment.
The study highlights the importance of protease-activated receptors (PARs) in cancer growth and development, with PH-binding motifs identified as a key platform for drug design. The researchers suggest that targeting PARs could provide an alternative to current oncogenic pathways.
Scientists have discovered the transporters responsible for delivering essential nutrients choline and ethanolamine to human cells. The study sheds light on the atomic structure of these transporters and their role in distributing micronutrients throughout the body, providing a foundation for new therapeutic approaches.
Researchers found no significant 'participation effect' in cancer trials, contrary to common belief among patients and healthcare providers. The study's results provide reassurance that not enrolling in a trial doesn't disadvantage a patient's survival outcomes.
A phase 3 trial found that pamrevlumab did not significantly improve lung function in patients with idiopathic pulmonary fibrosis. The study's results underscore the need for effective treatments to slow disease progression and improve patient outcomes.
Nach0 was trained on diverse tasks, including natural language understanding, synthetic route prediction, and molecular generation. The model performed well on molecular tasks using molecular data and outperformed ChatGPT, making it a significant step toward unlocking the full potential of LLMs for drug discovery.
Researchers have developed a synthesis method for introducing difluoromethyl groups into pyridines, a promising approach for new drugs and agrochemicals. The method allows precise introduction of the group at specific sites, overcoming a long-standing challenge in the chemistry field.
Researchers have discovered new binding sites for medications in proteins by heating them to body temperature, revealing previously unknown structures. This breakthrough could lead to the development of more effective drugs for various health conditions, including stroke, heart disease, and diabetes.
Insilico Medicine's lead compound demonstrates strong enzymatic activity, selectivity, and favorable ADME properties, as well as antitumor activity in various animal models. The company's generative AI-powered platform generated over 3,600 candidate molecules before identifying the promising lead compound.
Researchers at Insilico Medicine developed COSMIC, a new framework for molecular conformation space modeling that provides accurate insights into molecule positioning and activity. This enables faster and more efficient drug design decisions.
Researchers at Gladstone Institutes have identified a blood coagulation protein, fibrin, as the culprit behind toxic inflammation and neuron loss after a major head injury. This finding can inform new treatment strategies for traumatic brain injuries, which often lead to dementia, depression, and difficulty concentrating.
Researchers at University of Texas M. D. Anderson Cancer Center have developed a new method for developing immunotherapy drugs using engineered peptides. The approach improved tumor control and prolonged survival in preclinical models of breast cancer.
Researchers from the University of Cambridge used AI to identify compounds that block alpha-synuclein aggregation, a key step in treating Parkinson's disease. This breakthrough could lead to faster development of new treatments for the condition, which affects over six million people worldwide.